Blue­bird goes 2-for-2 on gene ther­a­pies at FDA ad­comm with thumbs up for beti-cel

For the sec­ond straight day, the FDA’s Cel­lu­lar, Tis­sue and Gene Ther­a­pies ad­comm vot­ed unan­i­mous­ly in fa­vor of FDA ap­prov­ing a blue­bird bio gene ther­a­py …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER